Keyphrases
Diabetes
100%
Liraglutide
100%
Clinical Development Programs
100%
Glycemic Control
42%
Cell Function
28%
Receptor Agonist
28%
Glucagon-like
28%
A1 Receptor
28%
Adverse Effects
14%
Disease Progression
14%
Minimal Risk
14%
Monotherapy
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Blood Pressure
14%
Randomized Controlled Study
14%
Hypoglycemia
14%
Current Treatment
14%
Weight Gain
14%
Type 2 Diabetic Patients
14%
Disease Course
14%
Serum Triglycerides
14%
Combination Therapy
14%
Hypoglycemia Risk
14%
Conventional Treatment
14%
Oral Treatment
14%
Oral Agents
14%
Incretin Response
14%
Medicine and Dentistry
Diabetes
100%
Liraglutide
100%
Glycemic Control
42%
Cell Function
28%
Hypoglycemia
28%
Glucagon-Like Peptide-1 Agonist
28%
Oral
28%
Monotherapy
14%
Maturity Onset Diabetes of the Young
14%
Disease Exacerbation
14%
Combination Therapy
14%
Triacylglycerol
14%
Blood Pressure
14%
Disease Course
14%
Patient with Type 2 Diabetes
14%
Incretin
14%
Adverse Effect
14%
Immunology and Microbiology
Glycemic Control
100%
Cell Function
66%
Agonist
66%
Glucagon-Like Peptide-1
66%
Blood Pressure
33%
Triacylglycerol Blood Level
33%
Incretin
33%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Hypoglycemia
28%
Glucagon Like Peptide 1 Receptor Agonist
28%
Maturity Onset Diabetes of the Young
28%
Combination Therapy
14%
Monotherapy
14%
Triacylglycerol
14%
Disease Exacerbation
14%
Disease Course
14%
Incretin
14%